WO1994008967A1 - Fluoroquinoline derivative - Google Patents
Fluoroquinoline derivative Download PDFInfo
- Publication number
- WO1994008967A1 WO1994008967A1 PCT/JP1993/001460 JP9301460W WO9408967A1 WO 1994008967 A1 WO1994008967 A1 WO 1994008967A1 JP 9301460 W JP9301460 W JP 9301460W WO 9408967 A1 WO9408967 A1 WO 9408967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- methoxy
- dihydro
- cyclopropyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention has the general formula (1)
- R 2 is a hydrogen atom, an amino group which may be protected, an amino group which may be protected or may be protected.
- R 5 represents the same meaning as a halogen atom, a lower alkyl group, an optionally protected hydroxyl group or R 2 which can be substituted on an arbitrary carbon atom, and R 6 represents a lower alkyl group; a is CH Z, a protected or unprotected have good nitrogen atom or an oxygen atom, n and m represents an integer of 0 to 4. However, n + m is an integer of 1-4.
- the present invention relates to a novel fluoroquinoline derivative and a salt thereof.
- the compound represented by the general formula (1) exhibits excellent antibacterial activity with good balance to both gram-positive bacteria and gram-negative bacteria, and a high blood concentration can be obtained by oral or parenteral administration. In addition, it is a highly stable drug with low toxicity, high photostability, low cytotoxicity under light irradiation, and extremely useful as a drug such as an antibacterial agent.
- quinolone antibacterial agents other than the above are known (for example, JP-A-59-67269, JP-A-59-221424, and 6 0 — 2 1 4 7 7 3 and 6 2 — 2 5 7 7 2 and 6 3 — 1 9 8 6 6 4) are suitable as parenteral preparations. However, few of them satisfy both the antibacterial activity and safety, and the development of a new synthetic antibacterial agent has been desired.
- the present inventors have conducted intensive studies to develop an excellent antibacterial agent.
- the compound represented by the general formula (1) and a salt thereof achieve the above object. And found the present invention.
- R 2 or R 5 in the general formula (1) an amino group which may be protected or an amino group which may be protected.
- the protecting group for the Q group include those commonly used in the art, and include, for example, trichloroethoxycarbonyl, tripromoxycarbonyl, benzyloxycanolevonyl, and p-toluene.
- the carboxyl group which may be protected may be any group which can be used as a protecting group for a normal carboxyl group, such as methyl, ethyl, n-propyl, i 1-propyl, n-butyl, t-butyl, s-butyl, benzyl, diphenylmethyl. Tritinole, p-dibenzobenole, p-methoxybenzenole, benzozoinolemetinole, acetinolemethyl , P-Nitro benzoyl olemethyl.
- Salts of the compound represented by the general formula (1) are generally known.
- a salt in a basic group such as an amino group or an acidic group such as a carboxyl group.
- Examples of the salt in a basic group such as an amino group include salts with a mineral acid such as hydrochloric acid or sulfuric acid, and organic carboxylic acids such as oxalic acid, formic acid, trichloroacetic acid, or trifluoroacetic acid.
- salts with sulfonates such as methansulfonate, p-toluenesulfonate or naphthalenesulfonate are examples of salts in acidic groups such as dicarboxylic acid groups.
- Salt with alkaline metal such as sodium or magnesium
- salt with alkaline earth metal such as calcium or magnesium
- ammonium salt dibenzylamine, N — Benzyl ⁇ -phenethylamine.
- N, N Salts with nitrogenous organic bases such as dibenzylethylenediamine or triethylamine, trimethylamine, triplimamine, viridine Salts such as N-methyldianiline, N-methylbiperidine, N-methylmorpholine, getinoleamine, and dicyclohexylamine.
- nitrogenous organic bases such as dibenzylethylenediamine or triethylamine, trimethylamine, triplimamine, viridine Salts such as N-methyldianiline, N-methylbiperidine, N-methylmorpholine, getinoleamine, and dicyclohexylamine.
- a lower alkyl group refers to an alkyl group having 1 to 6 carbon atoms, and is preferably a methyl group, an ethyl group, an n-propyl group, an i-propyl group, or an n-butyl group. Groups, i-butyl group, s-butyl group, t-butyl group and the like.
- the present invention when an isomer exists, includes all such isomers.
- the compound represented by the general formula (1) and a salt thereof are new compounds that have not been described in the literature, and can be produced, for example, as follows ;
- R z , R 5 and R 6 have the same meanings as described above, and R 3 and R 4 are the same or different and are carboxyl protecting groups
- X is a halogen atom
- X, and X 2 are B representing the same or different leaving group is — (CH 2 ) P —, one (CH 2 ) m — 0— (CH z ) n — or
- n + m is an integer of 1 to 4.
- the step of obtaining the general formula (5) from the general formula (2) is performed according to the method described in U.S. Pat. No. 3,590,036. Then, the compound of the general formula (3) or a salt thereof is reacted to obtain a compound of the general formula (4) or a salt thereof, which is deprotected and decarboxylated by a conventional method. And then introducing a carboxyl protecting group.
- Examples of the salt of the active methylene of the compound of the general formula (3) and the active methine of the compound of the general formula (4) include salts with alkali metals such as sodium and calcium. Is mentioned. ,
- the compound of the general formula (6) or a salt thereof may be prepared in a suitable solvent in the presence or absence of a base. It can be obtained by reacting the salt.
- examples of the leaving group for X and X 2 include a halogen atom such as chlorine, bromine and iodine, an alkyl sulfonyloxy group such as methansulfonyloxy, and the like.
- An arenesulfonyloxy group such as toluenesulfonyloxy and the like.
- the solvent used here is not particularly limited as long as it is a solvent inert to the reaction, but is preferably methanol, ethanol, or the like.
- Alcohols such as prono and phenol, ethers such as getyl ether, tetrahydrolan, and dioxane, and fragrances such as benzene, toluene and xylene Group hydrocarbons, N, N—dimethylformamide, N, N—amides such as dimethylacetamide, sulfoxides such as dimethylsulfoxide, water and the like.
- a mixture of two or more solvents may be used.
- the base examples include inorganic bases such as aluminum hydroxide, hydrogen carbonate, and alkali carbonate; metal hydrides such as sodium hydride and potassium hydride; Metal alkoxides, such as trium ethoxide and sodium methoxide, 1, 8 — diazabisik Organic bases such as [5,4,0] decane 7-ene (DBU) can be used.
- the amount of the organic base is preferably at least equimolar to the compound of the general formula (5) or a salt thereof. Is 1 to 5 moles.
- the amount of the compound of the general formula (6) or a salt thereof to be used is at least equimolar, preferably 1 to 5 times, the molar amount of the compound of the general formula (5) or a salt thereof.
- the reaction temperature is from 0 to the boiling point of the solvent used, preferably from 20 to 100, usually from 30 minutes to 50 hours, preferably from 3 to 20 hours.
- the compound of the general formula (7) or a salt thereof is subjected to a reaction known per se such as, for example, a decarboxylation reaction, a reduction reaction or a rearrangement reaction, thereby obtaining a compound of the general formula (1) or a salt thereof. It can be induced to its salt.
- the compound represented by the general formula (1) or a salt thereof can also be obtained as shown below.
- R, R 2, R 4 , R 5 , and R also have the same meanings as A, m, and n.
- the step of obtaining the general formula (8) from the general formula (5) is performed by converting the compound of the general formula (5) or a salt thereof to Chem. Ber. (Chem. Ber.) 99, pp. 2407 (1 966 years) Can be obtained by the method described.
- the compound of the general formula (8) or a salt thereof can be obtained by reacting, for example, trimethylsulfoxonium iodide in the presence of a base. Can be.
- Examples of the base used here include metal hydrides such as sodium hydride and potassium hydride.
- the compound of the general formula (9) or a salt thereof is converted into a compound of the general formula (1) by deprotection and decarboxylation, reduction or transfer. Alternatively, it can be induced to a salt thereof.
- the step of obtaining the general formula (9) from the general formula (8) can also be obtained by using a Simmons-Smith reaction or a 1,3-dipole addition reaction.
- the solvent used here examples include ethers such as getyl ether, tetrahydrofuran, and dioxane, and aromatic hydrocarbons such as benzene, toluene, and xylene.
- ethers such as getyl ether, tetrahydrofuran, and dioxane
- aromatic hydrocarbons such as benzene, toluene, and xylene.
- the compound represented by the general formula (8) and the general formula (9) or a salt thereof is a novel compound per se and forms a part of the present invention.
- the compound represented by the general formula (1) or a salt thereof can also be obtained as follows.
- the compound of the general formula (11) or a salt thereof is converted from the compound (5).
- the compound (7) can be derived from the compound of the general formula (-10) in the same manner as in the method for obtaining the compound (7).
- the compound represented by the general formula (11) or a salt thereof may be prepared, for example, using an Angewant'Hemi-International'Edition-In-English (Angew. Chem. Int. Ed. Engl.) Volume 18 Page 72
- the compound of the general formula (1) or a salt thereof can be derived according to the method described in (1977) and JP-B-62-37006.
- the compound represented by the general formula (1) or a salt thereof thus obtained can be isolated and purified by a conventional method.
- tablets, capsules, powders, syrups, granules, suppositories, ointments, and injections are used in the usual manner, using carriers normally used in the formulation. Etc. should be prepared.
- the administration method, dosage and number of administrations can be selected as appropriate according to the patient's symptoms. Oral or parenteral administration is usually used for adults (eg, injection, eye drops, administration to the rectal site, etc.).
- the obtained crystals are dissolved in methylene chloride 5 and, under cooling, 299.2 mg of diphenylphosphoryl azide and 107 mg of triethylamine are added, and the mixture is stirred at room temperature for 15 hours. .
- the reaction solution was concentrated under reduced pressure, and ethyl acetate 10 and 2N-hydrochloric acid 1Q were added to the obtained residue.
- the organic layer was separated, washed with water and saturated brine in that order, and then dried over sulfuric anhydride. Dry over sodium and remove the solvent under reduced pressure.
- To the resulting residue is added t-butanol 6, and the mixture is refluxed for 6 hours.
- Example 6 In the same manner as in 6, 1—cyclopropyl—6—fluorine 8—methoxy 7— (biperidine 1 4—inore) 1 1,4 1 dihydro 1 4 —Oxo 3 —quinolinecarboxylic acid methansulfonate is obtained.
- the 50 % growth inhibitory concentration (IC50) of the sample against the mouse lymphatic leukemia cell line L1210 was determined by measuring the MTT [3— (4,5—dimethyl thiazoyl 2-yl) 1-2,5— Diphenyltetrazolamide promide] method.
- a culture solution containing a 2-fold serial dilution of the sample (RPI containing 16% fetal serum in RPMI-164 medium) was used to obtain 2 X 10 ⁇ cells in 200
- the cells were cultured for one day, and 4 hours before the end of the culture, 5 rag of 1 M of a MTT solution was added.
- the insoluble formazan reduced by the mitochondrial dehydrogenase of the cells is removed by aspiration of the culture solution, and then extracted with dimethyl sulfoxide 100 if; Was measured for absorbance.
- Cell proliferation rate is indicated as a percentage of the formazan form of a test body was cultured in not Complex or cells (Control This setup roll), the Turks Tsu preparative method, IC 5. Was asked.
- Table 2 Compound IC so ⁇ g / 1
- Ciprofloxacin 7 7 [Test Example 3] It was measured by enhancing the cytotoxicity of the specimen to L1210 by ultraviolet irradiation. That is, the sample alone does not show cytotoxicity
- the fluoroquinoline derivative represented by the general formula (1) and its salt show excellent antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria, and have a high blood concentration by oral or parenteral administration. Since it is a compound with low toxicity, high photostability, low cytotoxicity under light irradiation, and high safety, it is extremely useful as a drug such as an antibacterial agent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93922063A EP0664288A1 (en) | 1992-10-09 | 1993-10-12 | Fluoroquinoline derivative |
KR1019950701357A KR100236852B1 (ko) | 1992-10-09 | 1993-10-12 | 플루오로 퀴놀린 유도체 |
US08/728,431 US5776948A (en) | 1992-10-09 | 1996-10-09 | Fluoroquinoline derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/312588 | 1992-10-09 | ||
JP31258892 | 1992-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994008967A1 true WO1994008967A1 (en) | 1994-04-28 |
Family
ID=18031012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001460 WO1994008967A1 (en) | 1992-10-09 | 1993-10-12 | Fluoroquinoline derivative |
Country Status (4)
Country | Link |
---|---|
US (1) | US5776948A (ja) |
EP (1) | EP0664288A1 (ja) |
KR (1) | KR100236852B1 (ja) |
WO (1) | WO1994008967A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63135372A (ja) * | 1986-11-18 | 1988-06-07 | ヘキスト・アクチエンゲゼルシヤフト | 光活性ジヤイレース阻害剤およびその製造法 |
JPH0193573A (ja) * | 1987-10-05 | 1989-04-12 | Toyama Chem Co Ltd | 新規なキノリン誘導体およびその塩 |
JPH01254666A (ja) * | 1988-04-02 | 1989-10-11 | Bayer Ag | キノロンカルボン酸及び1,8−ナフチリジン‐4−オンカルボン酸、その製造方法及び中間体としてのそれらの使用 |
JPH0245469A (ja) * | 1988-06-21 | 1990-02-15 | Pfizer Inc | 6―フルオロ―1,4―ジヒドロキノール―4―オン―3―カルボン酸誘導体及びその中間体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929613A (en) * | 1987-08-26 | 1990-05-29 | Warner-Lambert Company | Antibacterial agents |
US4880814A (en) * | 1987-11-13 | 1989-11-14 | Abbott Laboratories | 7-cycloalkyl naphthyridines |
US4945160A (en) * | 1988-11-22 | 1990-07-31 | Warner-Lambert Company | Preparation of certain 7-substituted quinolones |
JP2779948B2 (ja) * | 1989-04-04 | 1998-07-23 | 富山化学工業株式会社 | 新規なキノリン誘導体およびその塩 |
US5137892A (en) * | 1990-12-12 | 1992-08-11 | Abbott Laboratories | Quinoline, naphthyridine and pyridobenzoxazine derivatives |
ES2167329T3 (es) * | 1992-01-31 | 2002-05-16 | Chugai Pharmaceutical Co Ltd | Cristal de hidrato de derivado de acido quinolonacarboxilico. |
AU4780793A (en) * | 1992-07-22 | 1994-02-14 | Genelabs Technologies, Inc. | 2-aryl-4-quinolones as antitumor compounds |
US5527910A (en) * | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
DE4339134A1 (de) * | 1993-11-16 | 1995-05-18 | Bayer Ag | 1-(2-Fluorcyclopropyl)-chinolon- und -naphthyridoncarbonsäure-Derivate |
-
1993
- 1993-10-12 EP EP93922063A patent/EP0664288A1/en not_active Withdrawn
- 1993-10-12 KR KR1019950701357A patent/KR100236852B1/ko not_active IP Right Cessation
- 1993-10-12 WO PCT/JP1993/001460 patent/WO1994008967A1/ja not_active Application Discontinuation
-
1996
- 1996-10-09 US US08/728,431 patent/US5776948A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63135372A (ja) * | 1986-11-18 | 1988-06-07 | ヘキスト・アクチエンゲゼルシヤフト | 光活性ジヤイレース阻害剤およびその製造法 |
JPH0193573A (ja) * | 1987-10-05 | 1989-04-12 | Toyama Chem Co Ltd | 新規なキノリン誘導体およびその塩 |
JPH01254666A (ja) * | 1988-04-02 | 1989-10-11 | Bayer Ag | キノロンカルボン酸及び1,8−ナフチリジン‐4−オンカルボン酸、その製造方法及び中間体としてのそれらの使用 |
JPH0245469A (ja) * | 1988-06-21 | 1990-02-15 | Pfizer Inc | 6―フルオロ―1,4―ジヒドロキノール―4―オン―3―カルボン酸誘導体及びその中間体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0664288A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0664288A4 (ja) | 1995-08-16 |
EP0664288A1 (en) | 1995-07-26 |
KR100236852B1 (ko) | 2000-03-02 |
US5776948A (en) | 1998-07-07 |
KR950703533A (ko) | 1995-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4555684B2 (ja) | Pde4阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン | |
JP4493503B2 (ja) | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 | |
EP0482939A1 (en) | Isoquinolinone derivative | |
HUT75304A (en) | Perhydroisoindole derivatives as p substance antagonists | |
WO2005121123A1 (fr) | Composes utilises comme antagonistes de ccr5 | |
FI102752B (fi) | Menetelmä verenpainetta alentavien 4-alkyyli-imidatsolijohdannaisten v almistamiseksi | |
IL148218A (en) | History of phenylpiperazines, method of preparation and pharmaceutical preparations containing them | |
DE69204252T2 (de) | Chinoline Derivate, nützlich als Angiotensin-II-Antagonisten. | |
KR20090106633A (ko) | PDE5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-c]퀴놀린 화합물 | |
SA04250305B1 (ar) | مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية | |
JPH08509972A (ja) | ピリミジン誘導体 | |
AU606778B2 (en) | Derivatives of 2-{(4-piperidinyl)methyl}-1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics | |
CA2727669A1 (fr) | Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 | |
FR2753970A1 (fr) | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique | |
EP0861252B1 (fr) | Derives naphtamide de 3-beta-amino azabicyclo octane ou nonane, comme agents antipsychotiques | |
WO1994008967A1 (en) | Fluoroquinoline derivative | |
US4049816A (en) | Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones | |
JP2007507470A (ja) | ヒトorl1受容体に対するアゴニストとしてのビシクロ’3.1.1!ヘプタン置換ベンズイミダゾロン及びキナゾリノン誘導体 | |
JPH08151366A (ja) | 1−ヒドロキシインドール誘導体 | |
WO1990004590A1 (en) | Benzothiadiazepine derivatives | |
JP2001213877A (ja) | カルボスチリル誘導体の製造法 | |
US5559139A (en) | Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, and its pharmaceutical use | |
US20040006137A1 (en) | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone | |
JPH0436266A (ja) | フェニルスルフィニルアルキルカルボン酸誘導体 | |
JPH03145464A (ja) | 光学活性1,4―ジヒドロピリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 411802 Date of ref document: 19950410 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993922063 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993922063 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 728431 Date of ref document: 19961009 Kind code of ref document: A Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993922063 Country of ref document: EP |